The search for biomarkers for therapeutic response using traditional genomic sequencing and other omic approaches has not yielded clinically actionable tools for most patients.
The post-translational attachment of glycans to proteins is a distinct layer of omics not captured with traditional proteomics. These biomarkers have the potential to play a crucial role in early intervention and personalized therapy decisions. In the past, the complexity of data generated using mass spectrometry – which is the most reliable method for quantifying glycoproteins – made it difficult to analyze the glycoproteome at scale. Now, InterVenn has developed a platform capable of generating clinically relevant insights through the glycoproteome.
Join us for this insightful discussion about how InterVenn’s targeted glycoproteomic services are powering new clinical insights. Our speaker will be Dr. David Braun, presenting some of the exciting results from the Checkmate 9ER trial that were featured at ESMO last year, and discuss how glycoproteomic analysis could yield powerful prognostic and predictive biomarkers.